Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2013

View Archived Issues

Data reported from first trial of Thalagen gene therapy for beta-thalassemia

Resverlogix completes enrollment in phase II trial of RVX-208

Sucampo Pharmaceuticals reports data from ion channel activator study

Phase IIa study of Santarus' SAN-300 in rheumatoid arthritis begins

Constellation Pharmaceuticals synthesizes new bromodomain inhibitors

Primary endpoints achieved in two phase III trials of rolapitant

Vertex Pharmaceuticals designs novel agents for influenza

Characterization of a novel Abeta inhibitor for the treatment of Alzheimer's disease

Antisense Therapeutics reports data from interim analysis of ATL-1103

RedHill Biopharma reports promising data for RHB-105

Can-Fite BioPharma reports topline results from phase IIb study of CF-101

Kissei grants Pfizer development and commercialization rights for KUX-1151

Researchers from Fusion Pharma present a novel pan-BCR/ABL inhibitor, PF-114

Chinese herbal medicine demonstrates safety and efficacy in first U.S. trial in liver fibrosis

Researchers agree to repurpose experimental asthma drug for the treatment of cancer

Immune Response BioPharma announces development of a novel HIV/AIDS vaccine

Gilead Sciences and Selcia patent novel cyclophilin A inhibitors

Secukinumab filed in Japan by Novartis for psoriasis

Novartis presents additional clinical data for serelaxin

FDA extends action date for vedolizumab for ulcerative colitis

Takeda stops development of fasiglifam

Takeda submits NDA for fomepizole in Japan

Swedish Orphan Biovitrum temporarily withdraws NDA for Orfadin

IGFBP-7 serum levels correlate with clinical severity in patients with heart failure

Genzyme receives complete response letter for Lemtrada for relapsing MS

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...